Co-Diagnostics, Inc. will host a booth at Medlab Middle East 2022 in Dubai from January 24th to 27th


SALT LAKE CITY, January 21, 2022 /PRNewswire/Co-Diagnostics, Inc. (Nasdaq:CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for developing molecular diagnostic tests, today announced that it will host a booth at the upcoming Medlab Middle East 2022 trade show 24-27 January at the Dubai World Trade Centre.

Targeted at the global medical laboratory community and showcasing the latest laboratory innovations and technologies, the conference is expected to provide company representatives and distributors with the opportunity to showcase co-diagnostics products to a wide range of international customers.

To learn more about the conference, including details on in-person and virtual registration, please visit Attendees interested in learning more about the company and its products, including its upcoming rapid point-of-care and home PCR diagnostics platform, are invited to visit booth Z6-C26.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah Corporation, is a molecular diagnostics company that develops, manufactures and markets advanced diagnostics technology. The Company’s technology is used for tests that use the detection and/or analysis of nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to develop specific tests to locate genetic markers for use in industries other than infectious diseases and to license use of these tests to specific customers.

SOURCE Co-Diagnostic


Comments are closed.